As of Jun 28
| +0.035 / +4.00%|
The 4 analysts offering 12-month price forecasts for Cascadian Therapeutics Inc have a median target of 3.50, with a high estimate of 5.00 and a low estimate of 2.00. The median estimate represents a +284.62% increase from the last price of 0.91.
The current consensus among 5 polled investment analysts is to Buy stock in Cascadian Therapeutics Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.